Myogen is a biopharmaceutical company founded in 1996, dedicated to advancing cardiovascular health with innovative small molecule therapeutics. Their slogan "Advancing cardiovascular health with innovative small molecule therapeutics for unmet medical needs" reflects their mission. The company focuses on the discovery, development, and commercialization of small molecule therapeutics targeting cardiovascular disorders. With a strong emphasis on their advanced understanding of cardiovascular disease biology and clinical expertise in cardiovascular therapeutics, Myogen aims to address serious and debilitating cardiovascular disorders inadequately treated by existing therapies. The company's last investment was a $40.00M Series D investment on 29 August 2003, with participation from notable investors including New Enterprise Associates, Greenspring Associates, InterWest Partners, Sequel Venture Partners, JPMorgan Partners, CMEA Ventures, Pacific Rim Partners, and Perseus-Soros Biopharmaceutical Fund.
Myogen
Advancing cardiovascular health with innovative small molecule therapeutics for unmet medical needs.
General Information
BounceWatch is an independent company data service, not affiliated with Myogen. To contact Myogen, visit myogen.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Myogen compare?
A PDF of Myogen and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Myogen soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About Myogen
Business keywords: biopharmaceutical company, cardiovascular health, small molecule therapeutics, discovery, development, commercialization, clinical expertise, cardiovascular disorders, biology of cardiovascular disease, clinical development expertise, novel therapies, licensing, acquisition, unmet medical needs
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series D | $40.00M | 8 |
|
29 Aug 2003 |
| Series D | $14.00M | 2 |
|
03 Jan 2002 |
| Series D | $52.40M | - |
|
28 Aug 2001 |
| Series D | $63.37M | - |
|
01 Jun 2001 |
| Venture Round | $18.00M | - |
|
15 Dec 1999 |
Myogen Alternatives & Competitors
View All Alternatives
Innovative treatments for cancer and autoimmune disorders through pioneering small-molecule therapeu...
Aclipse develops novel and highly differentiated therapeutics to treat diseases with significant unm...
Focused on innovative small-molecule therapeutics, addressing unmet medical needs with strategic all...
FAQ About Myogen
Source: BounceWatch company record for Myogen, https://bouncewatch.com/company/myogen, updated 27 December 2024. When citing, please name BounceWatch and link this page.
